RT期刊文章SR电子T1贝伐单抗复发性恶性神经胶质瘤摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP 779 OP 787做10首页.1212/01. wnl.0000304121.57857.38 VO 70是10 A1。d·诺顿A1 g . s .年轻A1 K。Setayesh A1。Muzikansky A1 r . Klufas A1 g·l·罗斯A1。美国Ciampa A1 l . g . Ebbeling A1 b . Levy A1 j . Drappatz A1 s Kesari A1 p . y .温家宝年2008 UL http://n.首页neurology.org/content/70/10/779.abstract AB背景:贝伐单抗,人源化单克隆抗体对血管内皮生长因子,在复发性恶性神经胶质瘤可能活动。在复发有些病人出现开发nonenhancing浸润而不是增强肿瘤疾病。方法:我们回顾了连续55复发性恶性神经胶质瘤患者接受贝伐单抗和化疗来确定疗效,毒性和复发的模式。使用盲法,标准化的成像检查和定量体积分析,与贝伐单抗治疗的患者的复发模式相比,复发模式仅19个病人接受化疗。结果:总共有2.3%的患者完全缓解,31.8%部分反应,29.5%的最小响应,29.5%有稳定的疾病。中位数时间射线级数为19.3周。 Six-month progression-free survival (PFS) was 42% for patients with glioblastoma and 32% for patients with anaplastic glioma. In 23 patients who progressed on their initial therapy, bevacizumab was continued and the concurrent chemotherapy agent changed. In no case did the change produce a radiographic response, but two patients had prolonged PFS of 20 and 31 weeks. Recurrence pattern analysis identified a significant increase in the volume of infiltrative tumor relative to enhancing tumor in bevacizumab responders. Conclusions: Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas. At recurrence, continuing bevacizumab and changing the chemotherapy agent provided long-term disease control only in a small subset of patients. Bevacizumab may alter the recurrence pattern of malignant gliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth. AA=anaplastic astrocytoma; AG=anaplastic glioma; CR=complete response; GBM=glioblastoma; EIAED=enzyme-inducing antiepileptic drug; FLAIR=fluid-attenuated inversion recovery; KPS=Karnofsky Performance Status; MR=minimal response; PFS=progression-free survival; PR=partial response; rFPR=relative FLAIR progression ratio; rNTR=relative nonenhancing tumor ratio; T1W=T1-weighted; VEGF=vascular endothelial growth factor.

map